Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#181 / 200 Total
ARDX - Ardelyx Inc - Stock Price Chart
TickerARDX [NASD, RUT]
CompanyArdelyx Inc
CountryUSA
IndustryBiotechnology
Market Cap2.04BEPS (ttm)-0.29
P/E-EPS this Y-22.55%
Forward P/E71.80EPS next Y133.03%
PEG-EPS past 5Y28.61%
P/S12.82EPS next 5Y30.00%
P/B13.52EPS Q/Q11.99%
Dividend-Sales Q/Q304.81%
Insider Own3.86%Inst Own59.11%
Insider Trans-6.35%Inst Trans51.39%
Short Float15.08%EarningsMay 02/a
Analyst Recom1.00Target Price13.83
Avg Volume5.58M52W Range3.16 - 10.13
May-04-24 11:00AM Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 02:16PM Ardelyx Shares Rise After Q1 Beat (MT Newswires) +28.42%
09:57AM Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating (MT Newswires)
07:31AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:21AM Q1 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
May-02-24 08:58PM ARDX Stock Earnings: Ardelyx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:47PM Ardelyx: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 08:00AM Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings (GlobeNewswire)
ZEUS - Olympic Steel Inc. - Stock Price Chart
TickerZEUS [NASD, RUT]
CompanyOlympic Steel Inc.
CountryUSA
IndustrySteel
Market Cap640.53MEPS (ttm)3.74
P/E15.40EPS this Y-15.41%
Forward P/E15.22EPS next Y16.07%
PEG0.45EPS past 5Y5.44%
P/S0.30EPS next 5Y34.29%
P/B1.14EPS Q/Q-12.60%
Dividend0.91%Sales Q/Q-8.10%
Insider Own12.06%Inst Own87.64%
Insider Trans0.00%Inst Trans-0.72%
Short Float3.22%EarningsMay 02/a
Analyst Recom2.00Target Price73.00
Avg Volume81.00K52W Range40.85 - 73.49
Today 08:17AM Olympic Steel, Inc. (NASDAQ:ZEUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-04-24 03:08AM Olympic Steel Inc (ZEUS) (Q1 2024) Earnings Call Transcript Highlights: Robust Sales and ... (GuruFocus.com)
May-03-24 11:21PM Q1 2024 Olympic Steel Inc Earnings Call (Thomson Reuters StreetEvents) -9.63%
May-02-24 06:02PM Olympic Steel Inc (ZEUS) Q1 2024 Earnings: Navigating Market Challenges with Strategic ... (GuruFocus.com)
05:45PM Olympic Steel (ZEUS) Tops Q1 Earnings Estimates (Zacks)
04:44PM Olympic Steel: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM Olympic Steel Reports First-Quarter 2024 Results (Business Wire)
Apr-03-24 04:30PM Webcast Alert: Olympic Steel to Announce First-Quarter 2024 Financial Results After Market Closes on May 2, 2024 (Business Wire)
Mar-18-24 10:58AM 15 Biggest Steel Companies in the US (Insider Monkey)
Mar-12-24 10:30AM Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
LTRN - Lantern Pharma Inc - Stock Price Chart
TickerLTRN [NASD]
CompanyLantern Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap66.17MEPS (ttm)-1.47
P/E-EPS this Y-38.32%
Forward P/E-EPS next Y7.38%
PEG-EPS past 5Y-39.81%
P/S-EPS next 5Y-
P/B1.61EPS Q/Q-24.47%
Dividend-Sales Q/Q-
Insider Own26.83%Inst Own10.55%
Insider Trans-19.44%Inst Trans0.92%
Short Float6.32%EarningsMay 09/a
Analyst Recom2.00Target Price22.00
Avg Volume331.84K52W Range2.38 - 11.99
May-02-24 07:30AM Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM 3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
LPA - Logistic Properties of the Americas - Stock Price Chart
TickerLPA [AMEX]
CompanyLogistic Properties of the Americas
CountryUSA
IndustryShell Companies
Market Cap238.14MEPS (ttm)0.05
P/E156.13EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.73EPS Q/Q-133.94%
Dividend-Sales Q/Q-
Insider Own91.27%Inst Own11.49%
Insider Trans0.00%Inst Trans-
Short Float0.34%Earnings-
Analyst Recom-Target Price-
Avg Volume27.38K52W Range5.59 - 31.63
Mar-18-24 07:00AM LatAm Logistic Properties, S.A. Announces Milestone Lease Agreement in Peru (PR Newswire)
Mar-15-24 09:37AM two and LatAm Logistic Properties, S.A. to Hold Virtual Investor Day on Tuesday, March 19, 2024, at 2:00 p.m. ET (GlobeNewswire)
Mar-13-24 07:17PM two and LatAm Logistic Properties, S.A. Announce Effectiveness of Registration Statement on Form F-4 in Connection with Business Combination (GlobeNewswire)
Feb-20-24 09:00AM two and LatAm Logistic Properties S.A. Announce $15 Million Equity Investment at $10 per share (GlobeNewswire)
Jan-04-24 11:35AM Billionaire Louis Bacons 15 Long-Term Stock Picks (Insider Monkey)
Dec-14-23 08:15AM LatAm Logistic Properties S.A. Announces Sale of Colombia Warehouse Facility (GlobeNewswire)
Dec-12-23 08:00AM LatAm Logistic Properties S.A. and two Announce Public Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination (GlobeNewswire)
Oct-06-23 08:15AM LatAm Logistic Properties S.A. Announces New Leases for Facilities in Peru and Costa Rica (GlobeNewswire)
Aug-15-23 07:00AM two and LatAm Logistic Properties S.A. Agree to Combine, Creating a Leading Publicly Traded Developer, Owner, and Manager of Modern Logistics Real Estate in Central and South America (GlobeNewswire)
May-19-23 06:44AM With 55% ownership, two (NYSE:TWOA) boasts of strong institutional backing (Simply Wall St.)
THRY - Thryv Holdings Inc - Stock Price Chart
TickerTHRY [NASD, RUT]
CompanyThryv Holdings Inc
CountryUSA
IndustryInternet Content & Information
Market Cap770.17MEPS (ttm)-7.51
P/E-EPS this Y105.06%
Forward P/E18.22EPS next Y212.17%
PEG-EPS past 5Y-
P/S0.85EPS next 5Y-
P/B4.61EPS Q/Q-11.91%
Dividend-Sales Q/Q-4.86%
Insider Own13.27%Inst Own95.61%
Insider Trans0.20%Inst Trans1.62%
Short Float9.97%EarningsMay 02/b
Analyst Recom1.00Target Price44.67
Avg Volume151.28K52W Range15.99 - 26.42
May-03-24 05:05AM Is Thryv Holdings (THRY) on Track to be More Profitable? (Insider Monkey) -11.07%
03:16AM Thryv Holdings Inc (THRY) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-02-24 10:22PM Q1 2024 Thryv Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
12:55PM THRY Stock Earnings: Thryv Holdings Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:55AM Thryv Holdings Inc Reports Mixed Q1 2024 Results: SaaS Growth Strong Despite Overall Revenue Decline (GuruFocus.com)
07:35AM Thryv Announces $40 Million Share Repurchase Program (Business Wire)
07:30AM Thryv Grows SaaS Revenue 24% in First Quarter 2024, Raises Full Year SaaS Guidance (Business Wire)
Apr-11-24 10:43AM Wall Street Reclaims $16 Billion of Deals Lost to Private Credit (Bloomberg)
09:05AM Thryv To Release First Quarter Financial Results on Thursday, May 2 (Business Wire)
Apr-09-24 09:05AM Thryv Names Rees Johnson as New Chief Product Officer (Business Wire) +5.44%
ZVSA - ZyVersa Therapeutics Inc - Stock Price Chart
TickerZVSA [NASD]
CompanyZyVersa Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap4.14MEPS (ttm)-71.31
P/E-EPS this Y98.62%
Forward P/E-EPS next Y-206.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.20EPS Q/Q-6291.81%
Dividend-Sales Q/Q-
Insider Own1.17%Inst Own13.75%
Insider Trans0.00%Inst Trans-
Short Float6.14%EarningsMar 25/b
Analyst Recom1.00Target Price70.00
Avg Volume394.96K52W Range4.44 - 220.85
Apr-29-24 07:57AM ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease (GlobeNewswire) +15.63%
Apr-04-24 07:57AM ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
Feb-29-24 07:57AM ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
ATXI - Avenue Therapeutics Inc - Stock Price Chart
TickerATXI [NASD]
CompanyAvenue Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.87MEPS (ttm)4.87
P/E0.98EPS this Y58.16%
Forward P/E-EPS next Y9.76%
PEG-EPS past 5Y50.07%
P/S-EPS next 5Y-
P/B1.03EPS Q/Q358.44%
Dividend-Sales Q/Q-
Insider Own11.82%Inst Own2.75%
Insider Trans-89.69%Inst Trans-
Short Float0.49%EarningsMar 18/a
Analyst Recom1.00Target Price56.25
Avg Volume34.36K52W Range4.38 - 93.75
Apr-29-24 08:00AM Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire) -27.18%
Apr-24-24 07:30AM Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire) -29.63%
Mar-25-24 08:30AM Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-19-24 06:53AM ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-11-24 08:00AM Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire) -15.62%
Feb-22-24 08:30AM Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Jan-16-24 08:40AM Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) -11.03%
Jan-11-24 08:00AM Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
LFLY - Leafly Holdings Inc - Stock Price Chart
TickerLFLY [NASD]
CompanyLeafly Holdings Inc
CountryUSA
IndustryPharmaceutical Retailers
Market Cap6.55MEPS (ttm)-4.83
P/E-EPS this Y25.84%
Forward P/E-EPS next Y33.43%
PEG-EPS past 5Y-
P/S0.16EPS next 5Y-
P/B-EPS Q/Q93.51%
Dividend-Sales Q/Q-19.54%
Insider Own30.27%Inst Own11.18%
Insider Trans0.00%Inst Trans-35.58%
Short Float4.00%EarningsMay 09/a
Analyst Recom2.33Target Price4.48
Avg Volume69.24K52W Range1.90 - 16.00
Apr-24-24 04:05PM Leafly to Announce First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-01-24 06:33PM Leafly Holdings, Inc. (NASDAQ:LFLY) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.46%
Mar-28-24 08:53PM LFLY Stock Earnings: Leafly Holdings Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:04PM Leafly Holdings, Inc. Announces Appointment of Two Cannabis Industry Veterans to Its Board (Business Wire)
04:02PM Leafly Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Mar-05-24 05:15PM Leafly to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on March 28, 2024 (Business Wire) +7.40%
Dec-05-23 09:30AM Leafly 2023 Cannabis Strain of the Year is "Permanent Marker" (Business Wire) -6.28%
Nov-12-23 12:08PM Leafly Holdings, Inc. (NASDAQ:LFLY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:02PM Leafly Holdings, Inc. Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-20-23 12:00PM Leafly Celebrates 3rd Annual International Budtenders Day (Business Wire)
VIGL - Vigil Neuroscience Inc - Stock Price Chart
TickerVIGL [NASD, RUT]
CompanyVigil Neuroscience Inc
CountryUSA
IndustryBiotechnology
Market Cap113.87MEPS (ttm)-2.13
P/E-EPS this Y-8.33%
Forward P/E-EPS next Y-0.60%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.94EPS Q/Q-19.06%
Dividend-Sales Q/Q-
Insider Own60.34%Inst Own33.92%
Insider Trans0.02%Inst Trans28.17%
Short Float6.18%EarningsMar 26/b
Analyst Recom1.50Target Price16.75
Avg Volume87.31K52W Range2.50 - 11.11
Apr-17-24 04:05PM Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-26-24 01:53PM VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 (InvestorPlace) -7.00%
07:05AM Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:05AM Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer (GlobeNewswire) +9.18%
Mar-13-24 07:05AM Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-12-24 07:05AM Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire) -5.99%
Mar-06-24 04:25PM Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 (GlobeNewswire)
Feb-29-24 04:05PM Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 (GlobeNewswire)
Feb-07-24 04:05PM Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 04:30PM Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones (GlobeNewswire)
CTMX - CytomX Therapeutics Inc - Stock Price Chart
TickerCTMX [NASD]
CompanyCytomX Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap301.86MEPS (ttm)-0.02
P/E-EPS this Y-4286.00%
Forward P/E-EPS next Y-11.04%
PEG-EPS past 5Y67.21%
P/S2.98EPS next 5Y-0.90%
P/B-EPS Q/Q109.36%
Dividend-Sales Q/Q32.22%
Insider Own1.84%Inst Own47.89%
Insider Trans-5.69%Inst Trans-20.06%
Short Float5.37%EarningsMar 11/a
Analyst Recom2.57Target Price3.95
Avg Volume4.52M52W Range1.04 - 5.85
May-02-24 08:08AM CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-01-24 12:11PM Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally (InvestorPlace) +214.72%
11:43AM Why Is CytomX (CTMX) Stock Up 180% Today? (InvestorPlace)
08:00AM CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
Apr-03-24 08:00AM CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-21-24 08:00AM CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors (GlobeNewswire)
Mar-18-24 08:00AM CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-12-24 09:12AM Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today? (InvestorPlace) -14.34%
1⋯10⋯14151617181920
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.